Stay updated on IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision: v3.3.3 was added; HHS Vulnerability Disclosure and Revision: v3.3.2 were removed.SummaryDifference0.1%

- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedRevision history now lists version v3.3.2. The previous version v3.2.0 has been removed from the history.SummaryDifference0.1%

- Check54 days agoChange DetectedRemoved the government funding notice banner that warned about potential delays and operating status in the page header. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check68 days agoChange DetectedRecord History shows multiple version updates with changes to Study Status, Recruitment Status, Contacts/Locations, and Outcome Measures.SummaryDifference0.1%

- Check97 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference11%

- Check104 days agoChange DetectedChanged the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.SummaryDifference0.3%

Stay in the know with updates to IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IO102/IO103 Combo + Pembrolizumab in Melanoma Clinical Trial page.